Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib-Reference-Cited by-同舟云学术

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Published:2016-11-17 Issue:20 Volume:128 Page:2415-2422
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kumar Shaji K.¹^ORCID,LaPlant Betsy R.²,Reeder Craig B.³,Roy Vivek⁴,Halvorson Alese E.²,Buadi Francis¹,Gertz Morie A.¹,Bergsagel P. Leif³,Dispenzieri Angela¹,Thompson Melanie A.¹,Crawley Jamie¹,Kapoor Prashant¹,Mikhael Joseph³,Stewart Keith³,Hayman Suzanne R.¹,Hwa Yi L.¹,Gonsalves Wilson¹,Witzig Thomas E.¹,Ailawadhi Sikander⁴,Dingli David¹,Go Ronald S.¹,Lin Yi¹,Rivera Candido E.⁴,Rajkumar S. Vincent¹,Lacy Martha Q.¹

Affiliation:

1. Division of Hematology and

2. Department of Biostatistics, Mayo Clinic. Rochester, MN;

3. Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ; and

4. Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL

Abstract

Key Points The combination of ixazomib and dexamethasone has clinical activity in patients with relapsed and or refractory multiple myeloma. Higher dose of ixazomib leads to improved response rates but with higher rates of treatment related adverse events.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/20/2415/1396982/blood717769.pdf

Reference26 articles.

1. Proteasome inhibitors in multiple myeloma: 10 years later;Moreau;Blood,2012

2. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines;Kumar;Mayo Clin Proc,2009

3. Development of the proteasome inhibitor PS-341;Adams;Oncologist,2002

4. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies;Orlowski;J Clin Oncol,2002

5. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial;Richardson;Blood,2007

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma;Cancer Medicine;2024-07

2. No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma;Blood Reviews;2023-01

3. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience;Blood Cancer Journal;2022-12-06

4. Second and Third Line Treatment Strategies in Multiple Myeloma: a Referral-Center Experience;2022-09-06

5. An update on the safety of ixazomib for the treatment of multiple myeloma;Expert Opinion on Drug Safety;2022-09-02